Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Daewoong Co., Ltd. (003090.KS)
KRW16,820.00
-560.00 (-3.22%)
KR KSC Healthcare Drug Manufacturers - General
Address
35-14, Jajanggongdan 4-gil
Hwaseong-si, KR
Hwaseong-si, KR
CEO
Yeong-Hwan Yoon
Website
daewoongholdings.com
IPO
2000-01-04
ISIN KR7003090008
Description
Operating alongside its various subsidiaries, Daewoong Co., Ltd. is primarily engaged in the production and sale of pharmaceutical products. Additionally, the company generates income from real estate leasing. Established in 1961, the firm transitioned its name from Daewoong Pharmaceutical Co., Ltd. to its current designation, Daewoong Co., Ltd., in 2002. Its corporate headquarters are located in Seongnam-si, South Korea.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
KRW16,820.00
-560.00 (-3.22%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
68.7K
Beta
0.32
Float Shares
26.05M
Free Float %
63.7%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.61% | -6.59% | -13.84% | -24.17% | -16.63% | -3.97% | +0.49% | +39.23% | -39.91% | +79.63% | +761.41% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
16,820.00
DCF (Levered)
25,907.04
+54.0%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2025-08 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
1.73
Distress
Piotroski F-Score
4 / 9
Average
MOAT Score
4 / 10
Developing
Composite Rating
A-
Overall Score
4 / 5
High
DCF Score
4 / 5
High
ROE Score
4 / 5
High
ROA Score
4 / 5
High
D/E Score
1 / 5
Low
P/E Score
3 / 5
Medium
P/Book Score
5 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - General: +6.6%+6.8% ★ Q1'26: +2.3% (vs Q1'25)
-
EPS growth Drug Manufacturers - General: +18.2%+170.1% ★ Q1'26: +31.1% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - General: +36.0%+10.2% Q1'26: -7.4% (vs Q1'25)
-
EBIT margin Drug Manufacturers - General: +19.4%+12.6% Q1'26: +9.7% (vs Q1'25)
-
ROIC Drug Manufacturers - General: +10.2%+10.3% ★ Q1'26: +6.0% (vs Q1'25)
-
Share dilution Drug Manufacturers - General: +0.0%+42.2% Q1'26: +2.8% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - General: -0.29×2.72× Q1'26: 3.48× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. |
Dec 2029 1 Rev. Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
996.65B
est: 50.50B (+1,873.6%)
|
1.02T
est: 53.00B (+1,815.1%)
|
1.12T
est: 54.40B (+1,966.3%)
|
1.23T
est: 48.45B (+2,441.1%)
|
1.37T
est: 50.60B (+2,599.0%)
|
1.36T
est: 1.38T (-1.7%)
|
1.51T
est: 1.49T (+1.5%)
|
1.70T
est: 1.61T (+5.1%)
|
1.82T
est: 1.86T (-2.3%)
|
1.94T
est: 1.95T (-0.5%)
|
2.07T
est: 2.17T (-4.5%)
|
2.42T
2.42T – 2.42T
+11.8% YoY
|
2.71T
2.71T – 2.71T
+11.8% YoY
|
3.01T
3.01T – 3.01T
+11.1% YoY
|
3.31T
3.31T – 3.31T
+10.1% YoY
|
| EBITDA |
116.42B
est: 6.37B (+1,726.3%)
|
99.77B
est: 6.69B (+1,391.3%)
|
131.63B
est: 6.87B (+1,816.8%)
|
148.27B
est: 6.12B (+2,324.4%)
|
139.36B
est: 6.39B (+2,081.9%)
|
203.82B
est: 173.99B (+17.1%)
|
171.19B
est: 188.03B (-9.0%)
|
211.37B
est: 203.77B (+3.7%)
|
270.34B
est: 234.41B (+15.3%)
|
182.13B
est: 357.11B (-49.0%)
|
323.40B
est: 397.36B (-18.6%)
|
444.22B
444.22B – 444.22B
+11.8% YoY
|
496.59B
496.59B – 496.59B
+11.8% YoY
|
551.65B
551.65B – 551.65B
+11.1% YoY
|
607.60B
607.60B – 607.60B
+10.1% YoY
|
| EBIT |
84.12B
est: 4.79B (+1,654.9%)
|
62.11B
est: 5.03B (+1,134.6%)
|
81.41B
est: 5.16B (+1,476.5%)
|
70.37B
est: 4.60B (+1,430.1%)
|
90.19B
est: 4.80B (+1,777.7%)
|
155.12B
est: 130.85B (+18.6%)
|
182.45B
est: 141.40B (+29.0%)
|
163.29B
est: 153.24B (+6.6%)
|
216.52B
est: 176.28B (+22.8%)
|
123.34B
est: 299.07B (-58.8%)
|
260.52B
est: 332.78B (-21.7%)
|
372.02B
372.02B – 372.02B
+11.8% YoY
|
415.88B
415.88B – 415.88B
+11.8% YoY
|
461.99B
461.99B – 461.99B
+11.1% YoY
|
508.85B
508.85B – 508.85B
+10.1% YoY
|
| Net Income |
38.62B
est: 8.99B (+329.5%)
|
19.83B
est: 8.73B (+127.1%)
|
66.25B
est: 10.06B (+558.9%)
|
29.86B
est: 8.67B (+244.6%)
|
62.44B
est: 8.18B (+663.8%)
|
98.38B
est: 43.53B (+126.0%)
|
78.73B
est: 51.54B (+52.7%)
|
102.57B
est: 54.53B (+88.1%)
|
152.67B
est: 121.85B (+25.3%)
|
57.89B
est: 132.51B (-56.3%)
|
175.06B
est: 201.52B (-13.1%)
|
226.70B
226.70B – 226.70B
+12.5% YoY
|
262.39B
262.39B – 262.39B
+15.7% YoY
|
—
— – —
-100.0% YoY
|
—
— – —
|
| SGA |
119.82B
est: 10.10B (+1,086.3%)
|
135.93B
est: 10.60B (+1,182.3%)
|
156.27B
est: 10.88B (+1,336.3%)
|
188.66B
est: 9.69B (+1,846.8%)
|
253.40B
est: 10.12B (+2,403.9%)
|
261.30B
est: 275.69B (-5.2%)
|
290.73B
est: 297.93B (-2.4%)
|
341.20B
est: 322.87B (+5.7%)
|
375.66B
est: 371.41B (+1.1%)
|
400.74B
est: 399.42B (+0.3%)
|
452.42B
est: 444.44B (+1.8%)
|
496.85B
496.85B – 496.85B
+11.8% YoY
|
555.43B
555.43B – 555.43B
+11.8% YoY
|
617.01B
617.01B – 617.01B
+11.1% YoY
|
679.59B
679.59B – 679.59B
+10.1% YoY
|
| EPS |
906.60
est: 220.00 (+312.1%)
|
460.26
est: 213.60 (+115.5%)
|
1,534.00
est: 246.00 (+523.6%)
|
692.00
est: 212.00 (+226.4%)
|
1,423.96
est: 200.00 (+612.0%)
|
2,343.12
est: 1,065.00 (+120.0%)
|
1,894.69
est: 1,261.00 (+50.3%)
|
2,466.88
est: 1,334.00 (+84.9%)
|
3,691.68
est: 2,981.00 (+23.8%)
|
1,416.17
est: 2,279.00 (-37.9%)
|
3,824.66
est: 3,466.00 (+10.3%)
|
3,899.00
3,899.00 – 3,899.00
+12.5% YoY
|
4,513.00
4,513.00 – 4,513.00
+15.7% YoY
|
—
— – —
-100.0% YoY
|
—
— – —
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-15 | A- | 4/5 | 4/5 | 4/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-05-14 | A- | 4/5 | 4/5 | 4/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-05-13 | A- | 4/5 | 4/5 | 4/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-05-12 | A- | 4/5 | 4/5 | 4/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-05-11 | A- | 4/5 | 4/5 | 4/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-05-08 | A | 4/5 | 4/5 | 4/5 | 4/5 | 1/5 | 4/5 | 5/5 |
| 2026-05-07 | A | 4/5 | 4/5 | 4/5 | 4/5 | 1/5 | 4/5 | 5/5 |
| 2026-05-06 | A | 4/5 | 4/5 | 4/5 | 4/5 | 1/5 | 4/5 | 5/5 |
| 2026-05-04 | A | 4/5 | 4/5 | 4/5 | 4/5 | 1/5 | 4/5 | 5/5 |
| 2026-04-30 | A | 4/5 | 4/5 | 4/5 | 4/5 | 1/5 | 4/5 | 5/5 |
| 2026-04-29 | A | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 4/5 | 5/5 |
| 2026-04-28 | A | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 4/5 | 5/5 |
| 2026-04-27 | A | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 4/5 | 5/5 |
| 2026-04-24 | A | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 4/5 | 5/5 |
| 2026-04-23 | A | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-22 | A | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-21 | A | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-20 | A | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-17 | A | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-16 | A | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-15 | A | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 5/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-59.04B
OE per share TTM
-1,577.28
Owner's Yield
-6.66%
Maintenance CapEx ratio
187.77%
Maint CapEx / Avg PPE
45.1%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
731.80M
Shares Outstanding
40.89M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Nan-Young Jeong | Chief Executive Officer, President and Representative Director | — | male |
| Yeong-Hwan Yoon | Chairman and Chief Executive Officer | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 003090.KS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
